Literature DB >> 14718434

The repeatability of forced expiratory volume measurements in adults with cystic fibrosis.

Matthew B Stanbrook1, Mary Corey, D Elizabeth Tullis.   

Abstract

STUDY
OBJECTIVE: To determine the repeatability of measurements of FEV(1) in adults with lung disease due to cystic fibrosis (CF).
DESIGN: Single cohort study nested within a randomized controlled trial.
SETTING: Adult CF of a university teaching hospital. Subjects were participants in a randomized trial of an experimental mucolytic drug. PATIENTS: Twenty-one adults (mean age, 27.5 +/- 9.2 years [+/- SD]) with CF and mild-to-moderate airflow obstruction (FEV(1) 70 +/- 15% predicted). Patients were in clinically stable condition prior to and during the study.
INTERVENTIONS: Repeated FEV(1) measurements were obtained at specific times of the day for 9 consecutive days, for a total of 31 measurements from each subject. Statistical measures of repeatability were calculated. Variation over the course of 1 day and variation from 1 day to the next were examined separately. MEASUREMENTS AND
RESULTS: For day-to-day FEV(1) measurements, the within-subject SD was 0.145 L (4.5% of predicted), indicating greater variation compared to values previously established in normal subjects. The coefficient of repeatability indicated that day-to-day measurements could differ by as much as 13% of predicted in the absence of clinical change. For measurements within a single day, variation was not observed to be greater than normal.
CONCLUSIONS: In adults with CF, day-to-day variation in FEV(1) measurements is greater than normal and similar to that seen in other obstructive lung diseases. Changes in FEV(1) over time in adults with CF can likely be interpreted using the same criteria that apply to asthma or COPD.

Entities:  

Mesh:

Year:  2004        PMID: 14718434     DOI: 10.1378/chest.125.1.150

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Assessment of lung disease in children with cystic fibrosis using hyperpolarized 3-Helium MRI: comparison with Shwachman score, Chrispin-Norman score and spirometry.

Authors:  Edwin J R van Beek; Catherine Hill; Neil Woodhouse; Stanislao Fichele; Sally Fleming; Bridget Howe; Sandra Bott; Jim M Wild; Christopher J Taylor
Journal:  Eur Radiol       Date:  2006-08-29       Impact factor: 5.315

Review 2.  Asthma in Cystic Fibrosis: Definitions and Implications of This Overlap Syndrome.

Authors:  Chad R Marion; Manuel Izquierdo; Holly C Hanes; Christopher Barrios
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-09       Impact factor: 4.806

Review 3.  Multimodality molecular imaging of the lung.

Authors:  Delphine L Chen; Paul E Kinahan
Journal:  J Magn Reson Imaging       Date:  2010-12       Impact factor: 4.813

4.  Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study.

Authors:  David Taylor-Robinson; Margaret Whitehead; Finn Diderichsen; Hanne Vebert Olesen; Tania Pressler; Rosalind L Smyth; Peter Diggle
Journal:  Thorax       Date:  2012-05-03       Impact factor: 9.139

5.  The Dynamics of Disease Progression in Cystic Fibrosis.

Authors:  Frederick R Adler; Theodore G Liou
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

6.  Improved In vivo Assessment of Pulmonary Fibrosis in Mice using X-Ray Dark-Field Radiography.

Authors:  Andre Yaroshenko; Katharina Hellbach; Ali Önder Yildirim; Thomas M Conlon; Isis Enlil Fernandez; Martin Bech; Astrid Velroyen; Felix G Meinel; Sigrid Auweter; Maximilian Reiser; Oliver Eickelberg; Franz Pfeiffer
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

7.  Influence of the Vibralung Acoustical Percussor on pulmonary function and sputum expectoration in individuals with cystic fibrosis.

Authors:  Courtney M Wheatley; Sarah E Baker; Cori M Daines; Hanna Phan; Marina G Martinez; Wayne J Morgan; Eric M Snyder
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.